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Metastases are preceded by stochastic formation of a hospitable microenvironment
known as the premetastatic niche, which has been difficult to study. Herein, we
employ implantable polycaprolactone scaffolds as an engineered premetastatic niche
to independently investigate the role of interleukin‐10 (IL10), CXCL12, and CCL2 in
recruiting immune and tumor cells and impacting breast cancer cell phenotype via
lentiviral overexpression. Lentivirus delivered from scaffolds in vivo achieved
sustained transgene expression for 56 days. IL10 lentiviral expression, but not
CXCL12 or CCL2, significantly decreased tumor cell recruitment to scaffolds in vivo.
Delivery of CXCL12 enhanced CD45+ immune cell recruitment to scaffolds while
delivery of IL10 reduced immune cell recruitment. CCL2 did not alter immune cell
recruitment. Tumor cell phenotype was investigated using conditioned media from
immunomodulated scaffolds, with CXCL12 microenvironments reducing proliferation,
and IL10 microenvironments enhancing proliferation. Migration was enhanced with
CCL2 and reduced with IL10‐driven microenvironments. Multiple linear regression
identified populations of immune cells associated with tumor cell abundance. CD45+
immune and CD8+ T cells were associated with reduced tumor cell abundance, while
CD11b+Gr1+ neutrophils and CD4+ T cells were associated with enhanced tumor
cell abundance. Collectively, biomaterial scaffolds provide a tool to probe the
formation and function of the premetastatic niche.
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1 | INTRODUCTION
Metastasis is the single greatest contributor to cancer‐associated
deaths (Chaffer & Weinberg, 2011). The progression of metastasis is
characterized by the development of a permissive microenvironment
known as the premetastatic niche, typically in a distal organ such as
the lung. The seed and soil hypothesis, coined by Stephen Paget in
1889, hypothesized that the soil of distal organs becomes primed to
support the seed of the metastatic tumor cell (Paget, 1889). This
phenomenon was confirmed in a landmark study by Kaplan et al.
(2005). The steps directly preceding metastasis formation are
particularly difficult to probe for at least two reasons. First, the
premetastatic niche occurs in stochastic locations within a target
organ and the varied locations constitute a small percentage of the
organ, making them difficult to identify (Peinado, Lavotshkin, &
Lyden, 2011; Peinado et al., 2017). Second, strategies to probe the
premetastatic niche have often employed genetic modifications that
impact the entire organism, typically with off‐target effects on
primary tumor development (Peinado et al., 2011). Biomaterial
scaffolds have recently emerged as tools to investigate tumor cell
abundance in predefined sites and to alter the local microenviron-
ment without altering the primary tumor cells or host organism
(Aguado, Bushnell, Rao, Jeruss, & Shea, 2017; Aguado et al., 2016;
Aguado et al., 2018; Aguado et al., 2015; Azarin et al., 2015; Bersani
et al., 2014; Bushnell et al., 2019; Ko et al., 2012; J. Lee et al., 2012;
Rao et al., 2016).
Immune cells play a substantial role in the formation and function
of the premetastatic niche, influencing immune and tumor cell
abundance and stromal cell phenotype. The immune cells influence
these functions, in part, through cytokines and chemokines, which
influence both immune and tumor cells and play roles in tumor cell
survival, growth, migration, immune‐cell infiltration, and angiogenesis
(Crusz & Balkwill, 2015). CXCL12 or stromal‐derived factor 1 (SDF‐1)
is known to be a chemoattractant for breast cancer cells (Teicher &
Fricker, 2010) however; it also has broad effects on immune cells
(Zlotnik & Yoshie, 2000), fibroblasts (Orimo et al., 2005), and
endothelial cells (De Falco et al., 2004). Similarly, interleukin‐10
(IL10; Kundu, Beaty, Jackson, & Fulton, 1996; Luo et al., 2006) and
CCL2 (also known as MCP‐1; Kitamura et al., 2015; Qian et al., 2011)
have both been implicated in metastasis. IL10 is an immunosuppres-
sive cytokine associated with alternatively activated macrophages
(termed M2; Galdiero, Marone, & Mantovani, 2018) and are generally
believed to have tumor‐supportive effects. Alternatively, activated
macrophages also secrete CCL2, which can contribute to TH2‐
polarized immunity and prevent TH1 tumor‐killing immunity
(Galdiero et al., 2018). Many studies have investigated the role of
such immunomodulatory factors on metastasis through genetically
engineered mouse models that alter their expression systemically
(Kucia et al., 2005). However, the systemic nature of these models
often precludes evaluation of the local impact of immunomodulatory
factors within the niche. Biomaterials capable of localized gene
expression provide an enabling tool to investigate the role of these
factors, with the caveat that not all tissue specific cell types will be
fully recapitulated.
In this report, we hypothesized that local modulation of the
immune microenvironment could serve as a means to influence
tumor cell abundance and to dissect the contribution of specific
immune cell populations to the recruitment of tumor cells to a
metastatic site. Biomaterials that recruit metastatic cancer cells in
vivo are an emerging technology to investigate tumor cell abundance
and phenotype at a premetastatic niche (Aguado et al., 2017; Aguado
et al., 2016; Aguado et al., 2018; Aguado et al., 2015; Azarin et al.,
2015; Bersani et al., 2014; Ko et al., 2012; J. Lee et al., 2012; Rao
et al., 2016). First, they provide a defined site in vivo to which tumor
cells are recruited. Second, they are readily modifiable on a local
scale, such that the properties of the site may be altered without off‐
target effects on the host at large. Finally, modulating the
environment can be used to probe the contributions of individual
immune cell populations to the abundance and phenotype of tumor
cells within the niche. As a result, biomaterial scaffolds that model
the premetastatic niche in vivo provide an enabling tool to
investigate the development of the premetastatic niche, the
abundance of tumor cells, and the contribution of individual factors
to each of these processes (Aguado et al., 2017).
2 | MATERIALS AND METHODS
2.1 | Lentivirus production
Lentiviral production was performed as previously described (Gower
et al., 2014). Briefly, DNA encoding for eGFP, firefly luciferase
(FLUC), murine IL10, CCL2, or CXCL12 in a self‐inactivating lentiviral
vector cassette with UBC promoter was purchased from Vector
Builder in Stbl3 Escherichia coli stock. Bacteria expressing the pLenti
expression vector plasmids were produced and DNA was isolated via
endotoxin free maxi‐prep (Qiagen). Sanger sequencing was per-
formed to confirm integrity of the promoter regions and the
sequence of the cytokine of interest. Lentivirus was produced in
HEK‐293FT cells grown in Dulbecco’s modified Eagle’s medium with
10% fetal bovine serum (FBS). Lentiviral packaging vectors were
cotransfected with the lentiviral vector into HEK293FT cells using
Lipofectamine 2000 (Life Technologies). After 48 hr, the supernatant
was collected, and cell debris was removed via centrifugation.
Lentiviral particles were then concentrated using PEG‐it (System
Biosciences) and resuspended in sterile dPBS with 1M sucrose to
increase viral stability. Lentiviral titer was determined using qPCR
Lentivirus Titer Kit (Applied Biological Materials). Typical titers
ranged from 1e9 to 5e9 particles/ml.
2.2 | Scaffold fabrication and implantation
2.2.1 | Microsphere preparation
Polycaprolactone (PCL) microspheres were prepared as described
previously (Rao et al., 2016). Briefly, an emulsion of 6% (w/w) PCL
(inherent viscosity: 0.65–0.85 dl/g; Lactel Absorbable Polymers) in
dichloromethane with a 10% (w/v) poly(vinyl alcohol) solution was
made, followed by 10,000 rpm homogenization for 1 min. Dichlor-
omethane solvent was evaporated via stirring for 3 hr. Microspheres
were isolated by 2,000g centrifugation for 10min and washed in
deionized water more than five times. After 48 hr of lyophilization,
microspheres were ready for use.
2.2.2 | Scaffold fabrication
Microporous PCL scaffolds were fabricated by mixing microspheres
as prepared above and sodium chloride (250–425 μm in diameter
crystals) at a 1:30 (w/w) ratio (Sempertegui, Narkhede, Thomas, &
Rao, 2018) and pressed in a steel die for 45 s at 1,500 PSI. To fuse
polymer microparticles into a continuous structure around salt
crystals, disks were heated at 60°C for 5min per side. Salt was
removed by immersion in water with shaking for at least 1.5 hr.
Scaffolds were sanitized for animal studies by immersion in 70%
ethanol, rinsed with sterile water, and dried on a sterile surface.
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2.2.3 | Scaffold lentivirus loading
Using a micropipette, 2e7 viral particles (in 20 ul dPBS with 1M
sucrose) were added to the scaffold, allowed to dry for 2min, and
then immediately implanted into the mouse.
2.2.4 | Scaffold implantation
Animal studies were performed in accordance with institutional
guidelines and protocols approved by the University of Michigan
Institutional Animal Care and Use Committee. Scaffolds were
implanted into the peritoneal (periovarian) fat pads of 8‐week‐old
female BALB/c mice (Jackson Laboratory) as previously described
(Azarin et al., 2015). For the surgical implantation procedure, animals
were anesthetized via isoflurane (2%, inhaled), administered Carpro-
fen analgesia (5 mg/kg, subcutaneous injection), the belly was shaved
and prepped using a Betadine swab followed by an ethanol swab, and
this procedure was repeated three times. A fenestrated sterile drape
was applied over the surgical area and a 1–1.5‐cm incision was made
in the skin parallel to the top of the hip. Next, a <1‐cm incision was
made in the peritoneal wall and the fat pads were gently pulled out of
the peritoneal cavity and placed on sterile gauze. Scaffolds were
placed on the fat pad, which was then wrapped to enclose the
scaffold. Each fat pad was gently reinserted into the peritoneal cavity
taking care to keep the scaffold enclosed within the fat. The
peritoneal wall was closed with #5‐0 vicryl resorbable sutures
(Ethicon). The skin was then closed using sterile wound clips (Reflex
9mm; Roboz Surgical Instrument Co.).
2.3 | Tumor inoculation
For experiments in tumor‐bearing mice (Figures 2–5), tumor
inoculations were performed by injection of 2 × 106 4T1‐tdtomato‐
luc2 (Perkin Elmer) cells in 50 μl phosphate buffered saline (Life
Technologies) into the fourth right mammary fat pads of 10‐week‐old
female BALB/c mice (Jackson Laboratory) 7 days before implantation
of scaffolds and analyzed 14 days after inoculation. Cell lines were
confirmed to be pathogen free and authenticated by short tandem
repeat DNA analysis and compared to the ATCC STR profile
database (DDC Medical).
2.4 | In vivo bioluminescence imaging
Luciferase expression was monitored longitudinally using an IVIS imaging
system (Caliper). Mice were anesthetized with isoflurane and adminis-
tered an intraperitoneal injection of d‐luciferin (Caliper) at a dose of
150mg/kg. Animals were then placed in the imaging chamber and images
were acquired every 5min for a total of 30min or until the peak signal
F IGURE 1 Experimental platform and timeline. Microporous polycaprolactone scaffolds serve as a platform to probe the form and function
of the premetastatic niche. These scaffolds spontaneously recruit tumor cells upon implantation into a mouse with a primary breast tumor.
Next, the scaffold is loaded with immunomodulatory lentivirus and implanted into the peritoneal fat pad of either tumor free or Day 7 4T1
tumor‐bearing BALB/c mice. The experimental timeline included quantifying transduction efficiency and immune modulation via flow cytometry
in tumor free mice, quantifying tumor cell recruitment and immune modulation via flow cytometry in tumor‐bearing mice, and isolating scaffolds
from tumor‐bearing mice and generating conditioned media for in vitro assays at 7 days after implantation. Over Days 1–60, the transduction
efficiency of lentivirus was quantified by bioluminescent imaging [Color figure can be viewed at wileyonlinelibrary.com]
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was found for each mouse. Signal intensity is reported as integrated light
flux (photons/s) as calculated by Living Image Software (Caliper).
2.5 | Flow cytometry
Scaffolds were minced, digested using Liberase TL (Roche), and
strained through a 70‐μm filter to produce a single cell suspension.
Cells were pelleted via centrifugation at 500g for 5min. After
isolation of a single cell suspension, cells were blocked using anti‐
CD16/32 (Biolegend) and stained with anti‐mouse CD45 AF700
(Biolegend), CD11b V500, F4/80 PECy7, Gr1 PacBlue, Ly6C FITC
(for experiments with tdtomato+tumor cells present) or PE (for
experiments with GFP+lentivirus transduced cells present), and
CD11c APC for profiling innate immune cells. For profiling adaptive
immune cells, samples were stained with anti‐mouse CD45 AF700,
CD4 V500, CD8 FITC (for experiments with tdtomato+tumor cells
present) or PE (for experiments with GFP+lentivirus transduced cells
F IGURE 2 Lentiviral delivery from scaffolds implanted in peritoneal fat pad achieves sustained transgene expression in immune cells in
healthy mice. Scaffolds implanted into fat pad and loaded with firefly luciferase (FLUC) lentivirus demonstrate sustained transgene expression
over 56 days. Representative images in (a). Expression peaks at Day 7 and significantly higher (p < .05) than blank scaffolds at all time points
investigated. (b) Scaffolds implanted into fat pad and loaded with eGFP lentivirus demonstrate a significantly higher mean‐centered percentage
of GFP+ cells (*p < .05) at Day 7 after implantation. Flow cytometry evaluation of cells transduced by lentivirus for surface markers demonstrate
differential accumulation of immune populations with lentiviral delivery of GFP (c) as well as populations more or less likely to be transduced by
lentivirus (d) including innate immune cell populations CD45+, CD11b+F480+, CD11b+Gr1+, Ly6C+F480‐cells and adaptive immune cell
populations including CD45+, CD19+, CD4+, CD8+, CD49b+cells. (*p < .05 via two‐sided t test). Bars represent standard error of mean (SEM).
n > 3 mice per condition [Color figure can be viewed at wileyonlinelibrary.com]
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present), CD19 PacBlue, and CD49b PECy7. Samples were run on
MoFlo Astrios Flow Cytometer (Beckman Coulter) and data
processed using FlowJo (TreeStar Inc.) and MATLAB release 2018a.
2.6 | Generation of conditioned media
Scaffolds were isolated, separated from the fat pad, and placed in
600‐ul sterile Roswell Park Memorial Institute (RPMI) 1640 media
with nonessential amino acids, HEPES buffer, and without phenol red.
Scaffolds were then minced using a microfeather scalpel and
incubated at 37°C and 5% CO2 for 48 hr. After conditioning of
media, supernatant was collected into microcentrifuge tubes (MCTs)
and centrifuged at 2,000g for 5min at 4°C. Supernatant was then
transferred to a new MCT and stored at −80°C until use.
2.7 | Conditioned media assays
4T1‐tdTomato‐luc2 cells were thawed and allowed to grow to confluency
before passaging for proliferation, scratch, and mammosphere assays. All
assays were performed in 96‐well plates with 50 µl of conditioned media
and 50ul of serum‐free or serum‐containing RPMI 1640 as appropriate
for the assay. For all conditioned media assays, each condition was
compared to a FLUC control in the same mouse (FLUC loaded and
implanted into right fat pad and virus of interest loaded and implanted
into left fat pad). RPMI 1640 with nonessential amino acids, HEPES
buffer, and without phenol red, was used as a control for all assays. All in
vitro assays were performed at least three times.
2.7.1 | Proliferation assays
Cells were plated at 50,000 cells/well and the number of cells was
monitored once a day for 4 days using a plate reader with excitation at
554 nm and emission at 581 nm reading from the bottom of the plate.
2.7.2 | Scratch assays
Cells were plated at 100,000 cells/well and allowed to attach for
12 hr. After 12 hr, a p200‐pipette tip was used to create a scratch in
the center of each well spanning the length of the well. The plate was
gently shaken to remove any loosely attached cells. Next, the media
F IGURE 3 Lentiviral delivery of immunomodulatory factors from
scaffolds results in alteration of spontaneous tumor cell recruitment
in tumor‐bearing mice. Cells quantified by flow cytometry for CD45‐
tdTomato+ tumor cells and reported as the percentage tumor cells of
all singlets for FLUC, CCL2, CXCL12, and interleukin‐10 (IL10)
lentivirus delivery. Letter indicates significance p < .05 where a is
significantly altered from FLUC, b from CCL2, and c from CXCL12 via
Tukey’s multiple comparisons test following a one way analysis of
variance (ANOVA). Error bars represent SEM. n = 4 mice per
condition. FLUC, firefly luciferase; SEM, standard error of mean
F IGURE 4 Lentiviral delivery of immunomodulatory factors from scaffolds results in modulation of the scaffold immune microenvironment
in tumor‐bearing mice. Delivery of immunomodulatory lentivirus alters (a) the percentage of CD45+ cells of singlets and (b) individual immune
cell populations including innate CD11b+F480+ macrophages, CD11b+Gr1+ neutrophils, CD11b+Gr1+Ly6C‐myeloid–derived suppressor cells,
CD11c+F480+ dendritic cells, Ly6C+F480‐monocytes and adaptive CD4+T cells, CD8+T cells, CD19+B cells, and CD49b+NK cells as evaluated
by flow cytometry. Letter indicates significance p < .05 where a is significantly altered from FLUC, b from CCL2, c from CXCL12, and d from IL10
via Tukey’s multiple comparisons test following a one‐way ANOVA. Error bars represent SEM. n = 4 mice per condition. ANOVA, analysis of
variance; IL10, interleukin‐10; FLUC, firefly luciferase; SEM, standard error of mean
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FIGURE 5 Continued.
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was replaced with 50 ul of the appropriate conditioned media and
50 ul of RPMI 1640 with 10% FBS. Wells were imaged using a light
microscope immediately after scratch formation and imaged every
3 hr after scratch formation to monitor scratch closure. At 12 hr
following scratch formation, each well was imaged and evaluated for
full, partial, or no closure of the scratch.
2.7.3 | Mammosphere assays
Cells were plated at 10,000 cells/well in an ultra‐low attachment 96‐
well plate with 50 µl of mammosphere media and 50 ul of the
appropriate conditioned media. Mammosphere formation was
monitored with imaging via light microscope for 5 days and
evaluation of whole well tdTomato fluorescence using a plate reader
as with the proliferation assay above.
2.8 | Statistical analysis
All results are presented as mean ± standard error of mean (SEM).
Statistical comparisons of parameters between groups were made as
appropriate for each comparison, these comparisons are listed in the
figure captions. p < .05 was considered statistically significant.
Unsupervised hierarchical clustering was performed in MATLAB
release 2018a using the function clustergram on a matrix of the
percentages of each cell population determined by flow cytometry
(variables) for each scaffold (observations) with standardization
along the rows of data so all populations are on the same scale and
clustering for columns to observe the relationships of samples from
different lentiviral groups to each other. Similarly, the correlation
analysis was performed using the MATLAB function corr on the same
matrix and plotted using the heatmap function. Multiple linear
regression analysis was performed in Minitab v18.1 using the
multiple linear regression assistant.
3 | RESULTS
3.1 | Lentiviral delivery from scaffolds achieves
sustained transgene expression in immune cells in
vivo at the scaffold site
PCL scaffolds have been employed as a synthetic premetastatic niche
(Aguado et al., 2016; Bushnell et al., 2019; Rao et al., 2016), and here,
we investigated the ability to deliver lentivirus to achieve sustained
transgene expression as outlined in the experimental platform and
timeline in Figure 1. Transgene expression was analyzed after
implantation into the fat pad via delivery of FLUC lentivirus and
bioluminescence imaging (Figure 2a). We found expression was
stable for at least 56 days after implantation (Figure 2b). Expression
peaked at Day 7 after implantation (6.36E6 ± 1.98E6 photons/s for
FLUC loaded scaffolds and 1.81E4 ± 3.68E3 photons/s for blank
scaffolds) and was significantly higher than blank scaffolds at all time
points investigated (p < .05 via two‐tailed Student’s t test).
Next, we investigated the proportion and distribution of cells
recruited to the scaffold transduced by lentivirus, as we anticipated
that lentiviral delivery alone may alter immune cell recruitment.
Delivery of a GFP‐encoding lentivirus enabled assessment of the
percentage of GFP+ cells by flow cytometry. At Day 7 after
implantation, the mean‐centered percentage of GFP+ cells in
scaffolds with GFP delivered was 1.15 ± 0.79% (Figure 2b). In this
same experiment, we also evaluated the relative distribution of
immune cells with and without delivery of lentivirus (Figure 2c). We
found that delivery of lentivirus significantly enhanced abundance of
CD45+ immune cells, reduced abundance of CD11b+Gr1+neutro-
phils, reduced abundance of Ly6C+F480‐ monocytes, and increased
abundance of CD8+T cells relative to blank scaffolds.
We next investigated which cell types are transduced by the
lentivirus and express the lentiviral transgene. The cell types that
were transduced with the lentivirus were identified by comparing the
percentage of all cells for each immune population to the percentage
of GFP+ cells for a given population for both innate and adaptive
immune cell populations (Figure 2d). GFP+ cells that were transduced
with lentivirus were more likely to be CD45+ immune cells, CD11b
+F4/80+ macrophages, CD11b+Gr1+ neutrophils, and CD19+ B cells.
Interestingly, GFP+ cells that were transduced with lentivirus were
less likely to be Ly6C+F4/80‐monocytes, CD4+ helper T cells, CD8+
cytotoxic T cells, and CD49b+ natural killer cells.
3.2 | Lentiviral delivery of immunomodulatory
factors alters tumor cell abundance and modulates
the scaffold immune microenvironment in vivo
We next investigated sustained delivery from the PCL scaffold of
three immunomodulatory murine cytokines: CCL2 (MCP‐1), CXCL12
(SDF‐1), and IL10. We first validated enhanced local expression of
the delivered protein via imaging of eGFP expression and enzyme‐
linked immunosorbent assay (ELISA) for IL10 (Figure S1). We
F IGURE 5 Scaffold microenvironment immunomodulation alters tumor cell phenotype. (a) Experimental design overview. 4T1 tumor cells were
grown in vitro and treated with conditioned media generated from scaffolds loaded with (c) CCL2, (d) CXCL12, (e) IL10, or (c–e) FLUC from tumor‐
bearing mice in (c–e, left) proliferation assays where the number of cells per well was assessed by measuring tdTomato fluorescence via plate
reader, (c–e, middle) scratch migration assay where the number of scratches achieving complete, partial, or no closure was evaluated using light
microscopy, and (c–e, right) mammosphere assay where tumor cells were plated in ultra‐low attachment plates and allowed to grow as spheres in
the abundance of conditioned media and proliferation of spheres assessed by measuring tdTomato fluorescence via plate reader. The effect of
each immunomodulatory lentivirus is compared to an internal FLUC control for each set of mice. Error bars represent SEM. (*p < .05 via two‐sided t
test for comparisons between controls and delivered factors). n = 4 mice per condition with three technical replicates per biological
replicate. FLUC, firefly luciferase; IL10, interleukin‐10; SEM, standard error of mean [Color figure can be viewed at wileyonlinelibrary.com]
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hypothesized that delivery of these cytokines would alter the
recruitment of circulating tumor cells. Thus, we next investigated
the effect of immunomodulatory cytokine delivery on tumor cell
abundance in implanted scaffolds (Figure 3) that have previously
been shown to recruit tumor cells at this implant site and time scale
(Aguado et al., 2017; Aguado et al., 2016; Aguado et al., 2018;
Aguado et al., 2015; Azarin et al., 2015; Rao et al., 2016) with an
experimentally determined detection limit of five tumor cells in
250,000 total cells (0.002%) by flow cytometry (Azarin et al., 2015).
We found that IL10 significantly reduced the percentage of
tdTomato+4T1 metastatic tumor cells spontaneously arriving at the
scaffold relative to FLUC (0.06 ± 0.03% tdTomato+ of total cells for
IL10, 0.13 ± 0.04% tdTomato+ for FLUC, 0.09 ± 0.02% tdTomato+ for
CCL2, and 0.11 ± 0.04% tdTomato+ for CXCL12). No other statisti-
cally significant alterations in tumor cell abundance from FLUC
control were observed for CCL2 or CXCL12 delivery. We have
previously reported that delivery of control lentivirus (non‐immuno-
modulatory) does not alter tumor cell abundance in scaffolds relative
to blank (Azarin et al., 2015).
We anticipated that lentiviral delivery of immunomodulatory
cytokines would alter immune cell recruitment. Thus, the alterations
in immune cell abundance in the scaffold were next analyzed (Figure
4a). CXCL12 expression significantly enhanced the percentage of
CD45+ cells of total cells compared to FLUC control (35.9 ± 5.9%
CD45+ cells of total for CXCL12 and 31.4 ± 3.2% of CD45+ cells of
total for FLUC), while the delivery of IL10 significantly reduced the
percentage of CD45+ cells of total compared to FLUC control
(27.4 ± 4.1% of CD45+ cells of total for IL10 and 31.4 ± 3.2% of
CD45+ cells of total for FLUC). CCL2 delivery did not significantly
alter abundance of CD45+ immune cells relative to FLUC control.
In addition to altering total immune cell recruitment, we also
expected that lentiviral delivery of immunomodulatory cytokines
would alter the relative populations of various immune cell types.
Thus, we next investigated the relative distribution of immune cells
as a function of the immunomodulatory factors (Figure 4b). We found
a few statistically significant differences between immunomodulatory
conditions. In particular, we found a significant increase in CD11b
+F480+ macrophages in CXCL12 delivered scaffolds relative to CCL2
and IL10 scaffolds. We also found a significant decrease in CD11b
+Gr1+Ly6C‐myeloid–derived suppressor cells in CCL2‐delivered
scaffolds relative to CXCL12 and IL10 scaffolds. CCL2 also increased
Ly6C+F480‐monocyte abundance relative to IL10‐delivered scaffolds
and increased both CD8+T cells and CD19+ B cells relative to FLUC
and CXCL12 conditions. Finally, IL10 significantly increased CD8+ T
cells relative to both FLUC and CXCL12 conditions.
3.3 | Modulation of the scaffold immune
microenvironment exhibits differential effects on
tumor cell phenotype in vitro
Our hypothesis, that lentiviral delivery of immunomodulatory
cytokines would alter tumor cell recruitment, was supported by the
data, and we next investigated an effect on tumor cell phenotype. We
next evaluated scaffold microenvironments, with and without
immunomodulation, for the impact on tumor cell function or
phenotype using in vitro culture (Figure 5a). FLUC control scaffolds
were implanted in the right fat pad and scaffolds with a virus of
interest (CCL2, CXCL12, or IL10) implanted into the left fat pad of
the same mouse. Seven days after implantation, scaffolds were
explanted and used to generate conditioned media. The conditioned
media from CCL2 (Figure 5c), CXCL12 (Figure 5d), IL10 (Figure 5e),
or internal FLUC control (Figure 5a–e) scaffolds were then used for
various assays with tumor cells including proliferation (Figure 5c–e,
left column), scratch assay (Figure 5b, Figure 5c–e, middle column),
and mammosphere formation assay (Figure 5c–e, right column). Each
immunomodulatory lentivirus is compared to the FLUC control from
the same set of mice in these experiments. We reasoned that this
method would detect alterations to tumor cell behavior that are not
only a direct result of the delivered cytokine, but also indirect
alterations to the immune microenvironment that occur from the
delivered cytokine changing the immune populations present. CCL2
scaffold conditioned media treatment did not alter tumor cell
proliferation relative to serum‐free media or FLUC controls (Figure
5c, left). Interestingly, CCL2 scaffold conditioned media significantly
enhanced the number of wells with partial closure relative to FLUC
(11% partial in FLUC and 89% partial closure in CCL2; Figure 5c,
middle). CCL2 conditioned media also significantly reduced mammo-
sphere formation relative to serum‐free media control but did not
significantly alter mammosphere formation ability relative to FLUC
controls (Figure 5c, right). CXCL12 scaffold conditioned media
significantly reduced tumor cell proliferation (84,440 ± 41,000 cells/
well for FLUC and 54,400 ± 15,000 cells/well for CXCL12, Figure 5d,
left) but did not alter scratch closure (Figure 5d, middle) or
mammosphere formation (Figure 5d, right) relative to FLUC controls.
Finally, IL10 scaffold conditioned media significantly enhanced tumor
cell proliferation (17,700 ± 9,000 cells/well for FLUC and
35,900 ± 24,000 cells/well for IL10; Figure 5e, left), while signifi-
cantly reducing scratch closure (0% of scratches with no closure in
FLUC and 42% of scratches in IL10 with no closure; Figure 5e,
middle). IL10 scaffold conditioned media did not alter mammosphere
formation relative to FLUC control but reduced mammospheres
relative to serum‐free medium control (Figure 5e, right) similar to
both CCL2 and CXCL12 scaffold conditioned media.
3.4 | Correlation of scaffold‐secreted cytokines
with immune cell populations and tumor cell numbers
in vivo
We hypothesized that lentiviral delivery of immunomodulatory
cytokines and subsequent alteration of the immune microenviron-
ment would provide an opportunity to identify correlations between
individual immune cell populations with both tumor cells and other
immune cell populations. We next investigated the correlation of
individual immune cell populations with tumor cell abundance using
the flow cytometry data for immune and tumor cells. Unsupervised
hierarchical clustering was performed on flow cytometry data to
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investigate variations in the immune microenvironments across all
conditions (Figure 6a). While samples from the same cytokine
delivery condition often clustered together on the x‐axis, the
clustering also revealed additional sources of variability. Two major
clusters were identified with the first (left) encompassing all FLUC
and IL10 samples, all but one CXCL12 sample, and three of six CCL2
samples. The second cluster (right) contained one CXCL12 sample
and three of six CCL2 samples. Higher than average content of
CD19+ B cells and CD11b+Gr1+ neutrophils in the right branch
containing three of six CCL2 samples and one CXCL12 sample
appeared to be the factor differentiating these clusters. The first
cluster containing all FLUC, IL10, and most CXCL12 samples; this
cluster could be further subdivided into three clusters. The first of
these three branches contained samples with higher than average
CD45+ and CD11b+Gr1+Ly6C‐myeloid–derived suppressor cell
content. The second of these branches contained samples with
relatively high CD45‐tdTomato+ tumor cell content and CD45+ cell
content. The final branch contains samples with relatively high CD8+
T cell and Ly6C+F480‐monocyte content. Correlations between cell
types were not obvious by unsupervised clustering.
Correlation analysis was subsequently performed to broadly
identify relationships between each cell population in all immuno-
modulated scaffold microenvironments (Figure 6b) and add insight
into the interplay between individual cell populations within the
scaffold. Interestingly, CD11b+Gr1+ neutrophils, CD11c+ F480‐
dendritic cells, Ly6C+F480‐monocytes, CD4+ T cells, and CD19+ B
cells were positively associated with tumor cell numbers (r > 0), while
total CD45+ immune cell content, CD11b+F480+ macrophages,
CD11b+Gr1+Ly6C‐putative myeloid–derived suppressor cells,
CD8+T cells, and CD49b+ natural killer cells were all negatively
F IGURE 6 Lentiviral delivery of immunomodulatory factors from scaffolds results in multivariate modulation of the immune microenvironment
in tumor‐bearing mice. (a) Unsupervised hierarchical clustering of immune populations in scaffolds with FLUC, CCL2, CXCL12, or IL10 delivered.
(b) Correlation analysis of immune cell populations and tumor cell recruitment showing heatmap of Pearson correlation coefficient values for each
immune cell population and tumor cells identified as CD45‐tdTom+ across the range of scaffolds with FLUC, CCL2, CXCL12, or IL10 delivered.
n = 4 mice per condition. FLUC, firefly luciferase; IL10, interleukin‐10 [Color figure can be viewed at wileyonlinelibrary.com]
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correlated with tumor cell abundance (r < 0). In addition, some
immune cell populations were strongly positively correlated with
each other including CD11b+Gr1+ neutrophils and CD19+ B cells
(r = 0.75), CD11b+F480+ macrophages and CD11b+Gr1+Ly6C‐mye-
loid–derived suppressor cells (r = 0.672), and CD11b+Gr1+ neutro-
phils and Ly6C+F480‐monocytes (r = 0.67); while others had strong
negative correlations including CD11b+Gr1+Ly6C‐myeloid–derived
suppressor cells and Ly6C+F480‐ monocytes (r = −0.72). The key
players in tumor cell abundance were further investigated with a
stepwise multiple linear regression analysis to create a model that
explains the variability in the abundance of tumor cells at the
immunomodulated scaffold microenvironments by indicating correla-
tions between immune cell populations and tumor cell abundance
(Table 1, Figure S2). This model was created such that the percentage
of tumor cells relative to total cells was the output and the
percentage of each immune cell population (e.g., CD45+ total
immune cells, CD11b+F480+ macrophages) were continuous pre-
dictors. This analysis method created a model with the equation:
Tumor‐cells = 0.0794 − 0.004651 CD45 + 0.00438 Neutrophil +
0.0756 CD4 − 0.00298 CD8 and a model R2 = 69.69%, adjusted
R2 = 64.42%, and p < .001 for the model. The positive coefficients for
CD11b+Gr1+ neutrophils and CD4+ T cells indicate that these
positively correlate with tumor cell numbers, while total CD45+ cells
and CD8+ T cells negatively correlate with tumor cell numbers;
similar to what was observed with linear correlations (Figure 6b).
4 | DISCUSSION
Metastasis is responsible for 90% of cancer‐related deaths (Seyfried
& Huysentruyt, 2013). Targeting the development of the premeta-
static niche has the potential to significantly impact treatment of
metastasis. The premetastatic niche has been particularly difficult to
study, given the stochastic and focal nature of development in
premetastatic organs. In this study, we validate the use of biomaterial
scaffolds as a platform to engineer the premetastatic niche and
observe the impact on immune cell abundance and subsequent tumor
cell abundance. The standard platform for altering the properties of a
premetastatic site and observing the impact on metastasis has been
genetically engineered mouse models (Aguado et al., 2017). However,
disadvantages of these models include off‐target effects in tissues
other than the tissue of interest high development cost and time.
Biomaterial scaffolds have been used to recruit tumor cells in models
of breast (Aguado et al., 2016; Aguado et al., 2018; Aguado et al.,
2015; Azarin et al., 2015; Carpenter, Kwak, Peyton, & Lee, 2018; Rao
et al., 2016; Seib, Berry, Shiozawa, Taichman, & Kaplan, 2015),
prostate (Bersani et al., 2014), ovarian (de la Fuente et al., 2015),
melanoma (Ko et al., 2012), and leukemic (J. Lee et al., 2012) cancers.
The abundance of tumor cells at a site that is readily modifiable
provides a platform for probing the premetastatic and metastatic
niche; however, to this point, only individual factors have been
identified for their ability to enhance tumor cell abundance (Aguado
et al., 2016; Aguado et al., 2015; Azarin et al., 2015), yet no
alterations have been found that reduce tumor cell abundance
relative to control, nor has the interplay between the immune
microenvironment present in a scaffold and the subsequent
abundance of tumor cells been fully investigated. In particular, the
use of immunomodulation at the scaffold microenvironment facil-
itates a multivariate approach to understanding the premetastatic
niche. While only one factor was delivered in each case, it is clear
that a single factor has multifaceted effects on the abundance of
immune cell populations, their phenotype, and thus the recruitment
and abundance of tumor cells and their phenotype within the niche.
This paradigm of using a single factor to alter many properties of the
niche is advantageous because it allows for the modulation across a
range of different phenotypes to probe for common contributions to
tumor cell abundance and phenotype as we report herein.
Lentiviral gene delivery from biomaterial scaffolds has been
performed in the past with poly(lactide‐co‐glycolide) (PLG) scaffolds
(Azarin et al., 2015; Boehler et al., 2014; Gower et al., 2014; Liu et al.,
2016). In this study, PCL scaffolds were used, which have achieved
higher levels of tumor cell abundance relative to PLG (Rao et al.,
2016). Therefore, we hypothesized that we would have better
resolution for identifying effects of immunomodulation on tumor cell
abundance. We achieved long‐term sustained transgene expression
from scaffolds loaded with lentivirus and implanted into the fat pad,
similar to previous work (Gower et al., 2014). We found slightly
different cell populations stably expressing the lentivirus transgene
relative to previously reported (Gower et al., 2014). This result may
derive from mouse strain differences (BALB/c vs. CD1) or material
differences (PCL vs. PLG). As the cells transduced with the lentivirus
were more likely to be immune cells than nonimmune cells, this result
supports employing localized gene delivery for modulating the
immune microenvironment and provides further support for the
experimental approach of using immunomodulated microenviron-
ments to study metastasis.
While lentiviral delivery of immunomodulatory cytokines has also
been undertaken previously (Boehler et al., 2014; Gower et al., 2014;
Liu et al., 2016), this study investigates a range of inflammatory and
anti‐inflammatory factors to alter the immune microenvironment of
the foreign body response, and influence tumor cell abundance.
TABLE 1 Multiple linear regression for immunomodulated scaf-
folds identifies key immune cell populations correlating with tumor




Constant .118 0.08 0.05




% CD4+ of CD45+live cells .001 0.07 0.02
% CD8+ of CD45+live cells .039 −0.01 0.001
Note: Regression equation: Tumor‐cells = 0.08 − 0.01 CD45 + 0.01 Neu-
trophil + 0.07 CD4 − 0.01 CD8. Model R2 = 69.69%, Adjusted R2 = 64.42%,
p < .001.
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While modulation of total immune cell content was observed by flow
cytometry, the changes of relative immune cell populations were
smaller than expected. This result may arise from transducing only
1–2% of resident cells, even though detectable increases in the
delivered factor were observed by ELISA. However, these relatively
small changes in individual immune cell populations were able to
alter tumor cell abundance, with a decrease in tumor cells observed
for IL10 expression at scaffolds. This finding suggests that micro-
environments could be tailored to reduce tumor cell abundance
through modulating the immune microenvironment.
A major finding of this investigation was that the scaffold platform
can be used to dissect the contributions of immunomodulated
microenvironments to tumor cell phenotype in vitro. These experiments
were performed with whole scaffold conditioned media and 4T1 mouse
breast adenocarcinoma cells in vitro due to the relative difficulty of
ascertaining the effect of a microenvironment on recruited tumor cells
in vivo (Aguado et al., 2017). This approach also allowed for more
controlled understanding of the relationship between the microenvir-
onment and tumor cell phenotype. A direct analysis of recruited tumor
cells could be biased by abundance of different subpopulations of tumor
cells to distinct microenvironments. Interestingly, we found CCL2
modulated microenvironments enhanced migration relative to FLUC
control, consistent with previous findings that overexpression of CCL2
enhances metastasis (Kitamura et al., 2015; Qian et al., 2011). In
addition, we found CXCL12 modulated microenvironments significantly
reduced proliferation relative to the FLUC control in the same mouse.
This result is consistent with other reports demonstrating that
enhanced CXCL12 expression by the primary tumor inhibits tumor
growth and metastasis through regulation of antitumor immunity
(Williams et al., 2010). In addition, IL10‐modulated microenvironments
significantly enhanced proliferation relative to FLUC controls in the
same set of mice. As a potent anti‐inflammatory factor, IL10 is known to
enhance metastasis through suppression of various immune surveillance
mechanisms (Luo et al., 2006; Olkhanud et al., 2011), yet in other cases,
has been found to reduce metastasis (Kundu et al., 1996). By using
conditioned media from the modulated microenvironment, we removed
all cellular‐dependent mechanisms and relied only on secreted factors.
These results indicated that biasing the scaffold microenvironment
toward a more immune suppressive role has dual effects on tumor cells:
it reduces tumor cell abundance in the scaffold, yet enhances
proliferation. In addition, we found by scratch assay that IL10‐
modulated microenvironments reduce migration of tumor cells. This
result is consistent with the finding of reduced tumor cell abundance in
the scaffold. It is especially interesting that we find that simply
increasing the abundance of one cytokine had multifaceted effects on
both immune cells and tumor cell phenotype as we found CCL2
increased migration, CXCL12 decreased proliferation, and IL10 both
increased proliferation and decreased migration of tumor cells in vitro.
These findings highlight the potential of this platform to dissect the
complex contributors to metastasis and tumor cell phenotype within a
metastatic niche on a local scale as an alternative to primary tumor‐
driven (Williams et al., 2010) or genetically engineered mouse models
(Teicher & Fricker, 2010).
While we did not observe large changes in individual immune cell
populations present in the scaffold, we were able to use the sum total of
the immune microenvironment as evaluated by surface marker flow
cytometry to observe how delivery of various factors biased the
immune environment. This multifaceted approach allowed immune cell
populations that are positively and negatively correlated with tumor cell
abundance to be identified. Interestingly, we found CD11b+Gr1+neu-
trophils, CD11c+F480‐dendritic cells, Ly6C+F480‐monocytes, CD4+ T
cells, and CD19+ B cells to be positively associated with tumor cell
abundance, while overall CD45+, CD11b+F480+macrophages, CD11b
+Gr1+Ly6C‐putative myeloid–derived suppressor cells, CD8+ T cells,
and CD49b+ natural killer cells were all negatively correlated with
tumor cell abundance. Neutrophils, monocytes, and CD4+ T cells were
not surprising for their positive association with tumor cell abundance.
Similarly, the negative association of CD8+ T cells and CD49b+ natural
killer cells is to be expected as these are well known negative‐regulators
of tumor cells at metastatic or premetastatic sites. However, to our
knowledge, a positive association of dendritic cells and B cells with
breast cancer metastasis has not been previously reported and thus
may be unique to the engineered implant site. In addition, CD11b
+Gr1+Ly6C‐putative myeloid–derived suppressor cells were negatively
associated with tumor cell abundance, which was unexpected. This cell
population may be heterogeneous (Youn & Gabrilovich, 2010) and
contain neutrophils as well as myeloid–derived suppressor cells, which
may explain their negative impact on tumor cell abundance in this study.
We then created a multiple linear regression model with stepwise
validation of terms to find the populations that were significantly
associated with tumor cell abundance and build a model of tumor cell
abundance based on the abundance of immune cell populations. Similar
to simple correlation analysis and as would be expected based on the
literature, we found CD45+ and CD8+ T cells (Y. Lee et al., 2009) to be
negatively associated with tumor cell abundance while neutrophils
(Liang & Ferrara, 2016) and CD4+ T cells (DeNardo et al., 2009) were
positively associated with tumor cell abundance. This analysis indicates
that tumor cell abundance in a biomaterial scaffold in vivo can be
described reasonably well by knowing the relative proportions of
CD45+ immune cells, CD8+ T cells, CD4+ T cells, and CD11b+Gr1+
neutrophils. This finding is significant as it indicates the relative
distribution of immune cells at an implant could be potentially tracked
as a surrogate and correlate for tumor cell abundance in the implant.
In this study, we demonstrate the utility of lentiviral delivery from
biomaterial scaffolds to alter immune cell populations and tumor cell
abundance in vivo. Application of this technology toward dissecting the
role of various immune cell populations and secreted factors in metastasis
provides an engineering platform to molecularly dissect metastatic
processes, identify key pathways for intervention, and ultimately provide
new targets for the prevention and treatment of metastasis.
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